Phase II Study Of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) In Classical (HIV-Negative) And In AIDS-Associated Kaposi's Sarcoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary)
- Indications Kaposi's sarcoma
- Focus Therapeutic Use
- 06 Sep 2017 Biomarkers information updated
- 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.